These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 7660511

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. 1alpha,25-(OH)(2)-D(3) and its synthetic analogue decrease tumor load in the Apc(min) Mouse.
    Huerta S, Irwin RW, Heber D, Go VL, Koeffler HP, Uskokovic MR, Harris DM.
    Cancer Res; 2002 Feb 01; 62(3):741-6. PubMed ID: 11830528
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Selective inhibition of cyclooxygenase-2 (COX-2) by 1alpha,25-dihydroxy-16-ene-23-yne-vitamin D3, a less calcemic vitamin D analog.
    Aparna R, Subhashini J, Roy KR, Reddy GS, Robinson M, Uskokovic MR, Venkateswara Reddy G, Reddanna P.
    J Cell Biochem; 2008 Aug 01; 104(5):1832-42. PubMed ID: 18348265
    [Abstract] [Full Text] [Related]

  • 25. Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer.
    El Abdaimi K, Papavasiliou V, Rabbani SA, Rhim JS, Goltzman D, Kremer R.
    Cancer Res; 1999 Jul 15; 59(14):3325-8. PubMed ID: 10416587
    [Abstract] [Full Text] [Related]

  • 26. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
    Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM.
    Cancer Res; 2000 Sep 15; 60(18):5165-70. PubMed ID: 11016644
    [Abstract] [Full Text] [Related]

  • 27. Nitroxide tempo, a small molecule, induces apoptosis in prostate carcinoma cells and suppresses tumor growth in athymic mice.
    Suy S, Mitchell JB, Samuni A, Mueller S, Kasid U.
    Cancer; 2005 Mar 15; 103(6):1302-13. PubMed ID: 15685617
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Toxicity and dose-response studies of 1,25-(OH)2-16-ene-23-yne vitamin D3 in transgenic mice.
    Wilkerson CL, Darjatmoko SR, Lindstrom MJ, Albert DM.
    Clin Cancer Res; 1998 Sep 15; 4(9):2253-6. PubMed ID: 9748146
    [Abstract] [Full Text] [Related]

  • 32. Systemic interleukin 2 therapy for human prostate tumors in a nude mouse model.
    Triest JA, Grignon DJ, Cher ML, Kocheril SV, Montecillo EJ, Talati B, Tekyi-Mensah S, Pontes JE, Hillman GG.
    Clin Cancer Res; 1998 Aug 15; 4(8):2009-14. PubMed ID: 9717832
    [Abstract] [Full Text] [Related]

  • 33. Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion.
    Hedlund TE, Moffatt KA, Uskokovic MR, Miller GJ.
    Clin Cancer Res; 1997 Aug 15; 3(8):1331-8. PubMed ID: 9815816
    [Abstract] [Full Text] [Related]

  • 34. 1alpha,25-dihydroxy-16-ene-23-yne-vitamin D3 and 1alpha,25-dihydroxy-16-ene-23-yne-20-epi-vitamin D3: analogs of 1alpha,25-dihydroxyvitamin D3 that resist metabolism through the C-24 oxidation pathway are metabolized through the C-3 epimerization pathway.
    Reddy GS, Rao DS, Siu-Caldera ML, Astecker N, Weiskopf A, Vouros P, Sasso GJ, Manchand PS, Uskokovic MR.
    Arch Biochem Biophys; 2000 Nov 15; 383(2):197-205. PubMed ID: 11185554
    [Abstract] [Full Text] [Related]

  • 35. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.
    Barreto AM, Schwartz GG, Woodruff R, Cramer SD.
    Cancer Epidemiol Biomarkers Prev; 2000 Mar 15; 9(3):265-70. PubMed ID: 10750664
    [Abstract] [Full Text] [Related]

  • 36. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines.
    Moffatt KA, Johannes WU, Miller GJ.
    Clin Cancer Res; 1999 Mar 15; 5(3):695-703. PubMed ID: 10100724
    [Abstract] [Full Text] [Related]

  • 37. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
    Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW.
    Cancer Res; 1992 Mar 15; 52(6):1598-605. PubMed ID: 1371718
    [Abstract] [Full Text] [Related]

  • 38. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.
    Jackson JK, Gleave ME, Yago V, Beraldi E, Hunter WL, Burt HM.
    Cancer Res; 2000 Aug 01; 60(15):4146-51. PubMed ID: 10945622
    [Abstract] [Full Text] [Related]

  • 39. 24-Oxo metabolites of vitamin D3 analogues: disassociation of their prominent antileukemic effects from their lack of calcium modulation.
    Shiohara M, Uskokovic M, Hisatake J, Hisatake Y, Koike K, Komiyama A, Koeffler HP.
    Cancer Res; 2001 Apr 15; 61(8):3361-8. PubMed ID: 11309293
    [Abstract] [Full Text] [Related]

  • 40. Effectiveness of vitamin D analogues in treating large tumors and during prolonged use in murine retinoblastoma models.
    Albert DM, Kumar A, Strugnell SA, Darjatmoko SR, Lokken JM, Lindstrom MJ, Patel S.
    Arch Ophthalmol; 2004 Sep 15; 122(9):1357-62. PubMed ID: 15364716
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.